PI
NRIX icon

Pennant Investors’s Nurix Therapeutics NRIX Stock Holding History

Pennant Investors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-56,800
Closed -$1.19M – 35
2024
Q2 		$1.19M Hold
56,800
– – 0.31% 17
2024
Q1 		$835K Hold
56,800
– – 0.21% 17
2023
Q4 		$586K Buy
+56,800
New +$389K 0.13% 14

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Pennant Investors's NRIX Position: Q3 2024 in Review

Pennant Investors sold out of Nurix Therapeutics (NRIX) in Q3 2024, closing a stake of 56,800 shares — an estimated $1.19M sold.

Pennant Investors first reported a position in NRIX in Q4 2023 and held it in 3 quarters. The position peaked at $1.19M in Q2 2024. 172 funds tracked by Wall St. Rank hold NRIX as of Q3 2024.

  • Pennant Investors reported no remaining Nurix Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 56,800 Nurix Therapeutics shares in Q3 2024, an estimated $1.19M.
  • Pennant Investors first reported a position in Nurix Therapeutics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Nurix Therapeutics position peaked at $1.19M in Q2 2024.
  • 172 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.